JP2006524227A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006524227A5 JP2006524227A5 JP2006506588A JP2006506588A JP2006524227A5 JP 2006524227 A5 JP2006524227 A5 JP 2006524227A5 JP 2006506588 A JP2006506588 A JP 2006506588A JP 2006506588 A JP2006506588 A JP 2006506588A JP 2006524227 A5 JP2006524227 A5 JP 2006524227A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- medicament according
- independently
- unsubstituted
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 37
- 229910052739 hydrogen Inorganic materials 0.000 claims 25
- 239000001257 hydrogen Substances 0.000 claims 22
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 22
- 239000003937 drug carrier Substances 0.000 claims 15
- 229910052794 bromium Inorganic materials 0.000 claims 12
- 229910052801 chlorine Inorganic materials 0.000 claims 12
- 229910052731 fluorine Inorganic materials 0.000 claims 12
- 229910052740 iodine Inorganic materials 0.000 claims 11
- 241000710781 Flaviviridae Species 0.000 claims 10
- 230000009385 viral infection Effects 0.000 claims 10
- 208000036142 Viral infection Diseases 0.000 claims 9
- 230000002159 abnormal effect Effects 0.000 claims 9
- 125000002252 acyl group Chemical group 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 230000004663 cell proliferation Effects 0.000 claims 9
- 239000003085 diluting agent Substances 0.000 claims 9
- -1 diphosphate ester Chemical class 0.000 claims 9
- 229940002612 prodrug Drugs 0.000 claims 9
- 239000000651 prodrug Substances 0.000 claims 9
- 238000011321 prophylaxis Methods 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 238000011282 treatment Methods 0.000 claims 9
- 239000001177 diphosphate Substances 0.000 claims 8
- 235000011180 diphosphates Nutrition 0.000 claims 8
- 150000004712 monophosphates Chemical class 0.000 claims 8
- 239000002777 nucleoside Substances 0.000 claims 8
- 239000001226 triphosphate Substances 0.000 claims 8
- 235000011178 triphosphate Nutrition 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 125000003107 substituted aryl group Chemical group 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 229940024606 amino acid Drugs 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- 125000000262 haloalkenyl group Chemical group 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 150000003904 phospholipids Chemical class 0.000 claims 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052711 selenium Inorganic materials 0.000 claims 2
- ZZKNRXZVGOYGJT-VKHMYHEASA-N (2s)-2-[(2-phosphonoacetyl)amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CP(O)(O)=O ZZKNRXZVGOYGJT-VKHMYHEASA-N 0.000 claims 1
- 229940009098 aspartate Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 241000710778 Pestivirus Species 0.000 description 5
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 241001118702 Border disease virus Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45863503P | 2003-03-28 | 2003-03-28 | |
| PCT/IB2004/001429 WO2004084796A2 (en) | 2003-03-28 | 2004-03-29 | Compounds for the treatment of flaviviridae infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006524227A JP2006524227A (ja) | 2006-10-26 |
| JP2006524227A5 true JP2006524227A5 (enExample) | 2007-05-24 |
Family
ID=33098273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006506588A Pending JP2006524227A (ja) | 2003-03-28 | 2004-03-29 | フラビウイルス科ウイルス感染の治療のための化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20050049204A1 (enExample) |
| EP (1) | EP1626692A4 (enExample) |
| JP (1) | JP2006524227A (enExample) |
| CN (1) | CN1980678A (enExample) |
| AU (1) | AU2004224575A1 (enExample) |
| BR (1) | BRPI0408846A (enExample) |
| CA (1) | CA2529311A1 (enExample) |
| MX (1) | MXPA05010419A (enExample) |
| RU (1) | RU2005133093A (enExample) |
| WO (1) | WO2004084796A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| CA2410579C (en) | 2000-05-26 | 2010-04-20 | Jean-Pierre Sommadossi | Methods and compositions for treating flaviviruses and pestiviruses |
| CN1678326A (zh) | 2002-06-28 | 2005-10-05 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷 |
| CN101172993A (zh) | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷 |
| JP2006519753A (ja) | 2002-11-15 | 2006-08-31 | イデニクス（ケイマン）リミテツド | ２’−分枝ヌクレオシドおよびフラビウイルス科ウイルス突然変異 |
| MXPA05006230A (es) | 2002-12-12 | 2005-09-20 | Idenix Cayman Ltd | Proceso para la produccion de nucleosidos ramificados-2'. |
| WO2007047793A2 (en) * | 2005-10-19 | 2007-04-26 | University Of Georgia Research Foundation, Inc. | Cyclopentenol nucleoside compounds, intermediates for their synthesis and methods of treating viral infections |
| WO2008024763A2 (en) * | 2006-08-25 | 2008-02-28 | Wyeth | Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto |
| EA016830B1 (ru) * | 2006-09-11 | 2012-07-30 | Саузерн Рисерч Инститьют | Азольные нуклеозиды и их применение в качестве ингибиторов вариальных рнк- и днк-полимераз |
| WO2009146123A2 (en) * | 2008-04-03 | 2009-12-03 | Spring Bank | Compositions and methods for treating viral infections |
| WO2009152589A1 (en) | 2008-06-17 | 2009-12-23 | Universidade Federal De Minas Gerais-Ufmg | Use of paf receptor for treating infections caused by flaviviridae |
| WO2014186435A2 (en) | 2013-05-14 | 2014-11-20 | University Of Georgia Research Foundation, Inc. | Compositions and methods for reducing neointima formation |
| US20210353660A1 (en) * | 2018-10-04 | 2021-11-18 | Octagon Therapeutics Inc. | Pre-Activated Nucleoside IMPDH Inhibitors As Anti-Infective Drugs |
| US20230220386A1 (en) * | 2019-12-06 | 2023-07-13 | Medshine Discovery Inc. | Sirna conjugate, double-stranded sirna conjugate, salt thereof and application thereof |
| US20230123911A1 (en) * | 2020-01-31 | 2023-04-20 | Octagon Therapeutics, Inc. | Modulation of immune cells |
| US20230235330A1 (en) * | 2020-06-10 | 2023-07-27 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conjugate of double-stranded sirna analogue |
| JP2023528966A (ja) * | 2020-06-11 | 2023-07-06 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | 二本鎖ｓｉＲＮＡ類似体のコンジュゲート |
| WO2023155909A1 (zh) * | 2022-02-18 | 2023-08-24 | 南京明德新药研发有限公司 | 三氮唑核苷类似物及其作为嵌入基团的应用 |
| CN116808058A (zh) * | 2023-07-25 | 2023-09-29 | 徐州医科大学 | Pyrazofurin在制备治疗戊型肝炎疾病药物中的应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE29835E (en) * | 1971-06-01 | 1978-11-14 | Icn Pharmaceuticals | 1,2,4-Triazole nucleosides |
| US4211771A (en) * | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| US3798209A (en) * | 1971-06-01 | 1974-03-19 | Icn Pharmaceuticals | 1,2,4-triazole nucleosides |
| GB1414842A (en) * | 1972-02-11 | 1975-11-19 | Syntex Inc | 2,5-anhydro-d-alloses |
| US3960836A (en) * | 1974-07-22 | 1976-06-01 | Eli Lilly And Company | Acylated derivatives of pyrazofurin and process for their preparation |
| US5102883A (en) * | 1989-10-31 | 1992-04-07 | Du Pont Merck Pharmaceutical Company | Pyrimidine biosynthesis inhibitors useful as immunosuppressive agents |
| ZA931934B (en) * | 1992-03-18 | 1993-03-18 | Us Bioscience | Compostitions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals |
| GB9226729D0 (en) * | 1992-12-22 | 1993-02-17 | Wellcome Found | Therapeutic combination |
| US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
| US5767097A (en) * | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
| DK0879056T3 (da) * | 1996-01-23 | 2002-08-19 | Icn Pharmaceuticals | Modulation af Th1/Th2-cytokinekspression med ribavirin i aktiverede T-lymfocytter |
| US6150337A (en) * | 1996-01-23 | 2000-11-21 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes |
| US20020137696A1 (en) * | 1996-01-23 | 2002-09-26 | Robert Tam | Specific modulation of TH1/TH2 cytokine expression by ribavirin in activated T-lymphocytes |
| ES2195970T3 (es) * | 1996-10-16 | 2003-12-16 | Ribapharm Inc | L-ribavirina y usos de la misma. |
| US6509320B1 (en) * | 1996-10-16 | 2003-01-21 | Icn Pharmaceuticals, Inc. | Purine L-nucleosides, analogs and uses thereof |
| US6455690B1 (en) * | 1996-10-16 | 2002-09-24 | Robert Tam | L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine |
| DE69729887T2 (de) * | 1996-10-16 | 2005-07-28 | ICN Pharmaceuticals, Inc., Costa Mesa | Purin-L-Nukleoside, Analoga und deren Verwendung |
| US6887707B2 (en) * | 1996-10-28 | 2005-05-03 | University Of Washington | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA |
| AU740916B2 (en) * | 1996-10-28 | 2001-11-15 | University Of Washington | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA |
| DK0991415T3 (da) * | 1997-12-22 | 2003-06-16 | Schering Corp | Faste, oralt indgivelige dosisformer for ribavirin og fremgangsmåde til fremstilling af disse |
| US6423695B1 (en) * | 1998-01-13 | 2002-07-23 | Ribapharm, Inc. | Cytokine related treatments of disease |
| PT1058686E (pt) * | 1998-02-25 | 2007-01-31 | Raymond F Schinazi | 2'-fluoronucleósidos |
| AU766597B2 (en) * | 1998-05-15 | 2003-10-16 | Schering Corporation | Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis C infection |
| US6833361B2 (en) * | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
| TR200101085T2 (tr) * | 1998-10-16 | 2001-08-21 | Schering Corporation | Kronik hepatit C enfeksiyonlu hastalarda algılanabilir HCV-RNA'nın yok edilmesi için birleşik ribavirin-interferon alfa tedavisi |
| MY125300A (en) * | 1999-02-26 | 2006-07-31 | Inst Of Molecular And Cell Biology | Synergistic combination for treatment of viral-mediated diseases |
| US6495677B1 (en) * | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
| US6455508B1 (en) * | 2000-02-15 | 2002-09-24 | Kanda S. Ramasamy | Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides |
| US7056895B2 (en) * | 2000-02-15 | 2006-06-06 | Valeant Pharmaceuticals International | Tirazole nucleoside analogs and methods for using same |
| KR20030005197A (ko) * | 2000-02-18 | 2003-01-17 | 샤이어 바이오켐 인코포레이티드 | 뉴클레오시드유도체를 이용한 플라비바이러스 감염의 치료또는 예방 방법 |
| US7094770B2 (en) * | 2000-04-13 | 2006-08-22 | Pharmasset, Ltd. | 3′-or 2′-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| CA2410579C (en) * | 2000-05-26 | 2010-04-20 | Jean-Pierre Sommadossi | Methods and compositions for treating flaviviruses and pestiviruses |
| US6815542B2 (en) * | 2000-06-16 | 2004-11-09 | Ribapharm, Inc. | Nucleoside compounds and uses thereof |
| US20030008841A1 (en) * | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| JP2004533805A (ja) * | 2000-10-18 | 2004-11-11 | フアーマセツト・リミテツド | 疾患細胞中の核酸の多重定量 |
| KR20090089922A (ko) * | 2000-10-18 | 2009-08-24 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
| US7105499B2 (en) * | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| SI1355916T1 (sl) * | 2001-01-22 | 2007-04-30 | Merck & Co Inc | Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze |
| GB0112617D0 (en) * | 2001-05-23 | 2001-07-18 | Hoffmann La Roche | Antiviral nucleoside derivatives |
| GB0114286D0 (en) * | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| AU2002330154A1 (en) * | 2001-09-28 | 2003-04-07 | Centre National De La Recherche Scientifique | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
| JP2005536440A (ja) * | 2001-09-28 | 2005-12-02 | イデニクス（ケイマン）リミテツド | ４’位が修飾されたヌクレオシドを使用するフラビウイルスおよびペスチウイルスの治療のための方法および組成物 |
| BR0307712A (pt) * | 2002-02-14 | 2005-05-24 | Pharmasset Ltd | Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal |
| CN1678326A (zh) * | 2002-06-28 | 2005-10-05 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷 |
| US20040067877A1 (en) * | 2002-08-01 | 2004-04-08 | Schinazi Raymond F. | 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections |
| KR20050040912A (ko) * | 2002-08-01 | 2005-05-03 | 파마셋 인코포레이티드 | 플라비비리다에 감염 치료용의 비사이클로[4.2.1]노난시스템을 가지는 화합물 |
-
2004
- 2004-03-29 CA CA002529311A patent/CA2529311A1/en not_active Abandoned
- 2004-03-29 RU RU2005133093/04A patent/RU2005133093A/ru not_active Application Discontinuation
- 2004-03-29 WO PCT/IB2004/001429 patent/WO2004084796A2/en not_active Ceased
- 2004-03-29 JP JP2006506588A patent/JP2006524227A/ja active Pending
- 2004-03-29 CN CNA2004800117467A patent/CN1980678A/zh active Pending
- 2004-03-29 BR BRPI0408846-8A patent/BRPI0408846A/pt not_active IP Right Cessation
- 2004-03-29 US US10/812,448 patent/US20050049204A1/en not_active Abandoned
- 2004-03-29 EP EP04724085A patent/EP1626692A4/en not_active Withdrawn
- 2004-03-29 AU AU2004224575A patent/AU2004224575A1/en not_active Abandoned
- 2004-03-29 MX MXPA05010419A patent/MXPA05010419A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006524227A5 (enExample) | ||
| Sredni et al. | The immunomodulator AS101 administered orally as a chemoprotective and radioprotective agent | |
| BR0316397A (pt) | Tiouréias aril substituìdas e compostos relacionados como inibidores de replicação viral | |
| JP2005506352A5 (enExample) | ||
| TW200600492A (en) | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | |
| JP2005533824A5 (enExample) | ||
| JP2004519469A5 (enExample) | ||
| KR20160128305A (ko) | Hbv 감염의 치료를 위한 병용 요법 | |
| UA92746C2 (en) | Thiazole compounds and methods of use | |
| RU2005133093A (ru) | Соединения для лечения флавивирусных инфекций | |
| RU2008139195A (ru) | Замещенные арилсульфанамиды как противовирусные средства | |
| RU2010154173A (ru) | Режим введения нитрокатехолов | |
| EP1494659B1 (en) | Pharmaceutical composition comprising an alpha-ketoalkanoic acid ester or -amide and lactic acid or a lactic acid salt | |
| RU2001113268A (ru) | Сочетанная терапия рибавирином и интерфероном α для удаления определяемой рнк вируса гепатита с у пациентов с хроническим гепатитом с | |
| RU2005133665A (ru) | Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств | |
| JP2005532269A5 (enExample) | ||
| JP2005527575A5 (enExample) | ||
| RU2006104024A (ru) | Каппа-агонисты, в особенности для лечения и/или профилактики синдрома раздраженной толстой кишки | |
| RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 | |
| ES2272383T3 (es) | Uso de un agente que mejora la funcion astrocitica para el tratamiento de la enfermedad de parkison. | |
| JP5786714B2 (ja) | 神経障害性疼痛の治療剤又は予防剤 | |
| PT1556027E (pt) | Aminoácido modificado 5-cnac para a inibição de agregação de plaquetas | |
| US7906486B2 (en) | Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa | |
| KR20070012522A (ko) | 면역조절제 화합물로의 호흡기 바이러스 감염의 치료 및예방 | |
| JP2006516576A5 (enExample) |